Dottorato in Fisiopatologia Medica

Contatti

Supervisore

Francesco Giuseppe De Rosa

Curriculum vitae

Curriculum Vitae

Tesi di dottorato

"Physiopathology Of Infections In Patients With Permanently Implanted Heart Care"

 

In recent decades there has been a rapid increase in the use of implantable cardiac assist devices in patients with advanced heart failure, as data in the literature have shown that their use has a survival advantage over maximal medical therapy. An increase in complications has accompanied the increasing use of these devices. Infections are one of the major medical complications associated with permanent cardiac devices, not only because of the "invasive" nature required for implantation but also because of the dysregulation of the immune system and the chronic inflammatory state associated with the underlying heart failure. The significant sources of infection are contamination by the skin flora during the placement of the device. In the alternative, the exit-site of the driveline, i.e. the cable connecting the device to an external generator, is often the entry point of microorganisms that, following the course of the generator cables, can reach the device, causing infections. Also, the ability of pathogens to form a biofilm, a matrix that is difficult to penetrate by antibiotics, plays a central role in making the infectious process chronic linked to implantable devices. Usually, the skin surface is colonized by a resident microbial population, stable over time with different characteristics concerning the anatomical site explored. It can't, therefore, be hypothesized that malnutrition, comorbidities, and frequent hospitalizations to which these patients are subject are elements of vulnerability, able to determine the dysbiosis of the resident skin flora, reducing the diversity of the skin microbiota and finally encouraging colonization and/or infection by pathogenic species with the prevalence of multiresistant strains such as MRSA.

Attività di ricerca

Projects

- Epidemiology & treatment of infections by Multidrug-resistant organisms.

- Infections during Extracorporeal membrane Oxygenation.

- Pharmacokinetic of antibiotics.

- Nosocomial infections in ICU.

Stays abroad

Resident at Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Congresses

- Speaker at conferences on viral hepatitis and nosocomial infections.

- Oral communication ECCMID 2020

Publications

Calcagno A, Simiele M, Motta I, Mornese Pinna S, Bertucci R, D'Avolio A, Di

Perri G, Bonora S. Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration

in the Cerebrospinal Fluid of Three HIV-Positive Patients. AIDS Res Hum

Retroviruses. 2016 Mar 14.

- Boglione L, Mornese Pinna S, De Nicol. A, Cusato J, Cariti G, Di Perri G,

D'Avolio A. Treatment with direct-acting antiviral agents of hepatitis C virus

infection in injecting drug users: A prospective study. J Viral Hepat. 2017 Mar

26.

- Boglione L, De Nicol. A, Mornese Pinna S, Cusato J, Favata F, Ariaudo A,

Carcieri C, Cariti G, Di Perri G, D'Avolio A. Role of simeprevir plasma

concentrations in HCV treated patients with dermatological manifestations.

Dig Liver Dis. 2017 Jun;49(6):705-708.

- Boglione L, Pinna SM, Cardellino CS, De Nicol. A, Cusato J, Carcieri C, Cariti G,

Di Perri G, D'Avolio A. Treatment with daclatasvir and sofosbuvir for 24 weeks

without ribavirin in cirrhotic patients who failed first-generation protease

inhibitors. Infection. 2017 Feb;45(1):103-106.

- Mornese Pinna S, Scarvaglieri E, Milia MG, Imperiale D, Ghisetti V, Audagnotto

S, Prochet A, Lipani. Detectable cerebrospinal fluid JCV DNA in late-presenting

HIV-positive patients: beyond progressive multifocal leukoencephalopathy? J

Neurovirol. 2017 Oct;23(5):763-767.

- Cusato J, De Nicol. A, Boglione L, Favata F, Ariaudo A, Mornese Pinna S, Guido

F, Avataneo V, Carcieri C, Cariti G, Di Perri G, D'Avolio A. Influence of ABCB11

and HNF4α genes on daclatasvir plasma concentration: preliminary

pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017

Oct 1;72(10):2846-2849.

- Cusato J, Boglione L, De Nicol. A, Favata F, Ariaudo A, Mornese Pinna S, Guido

F, Avataneo V, Cant. M, Carcieri C, Cariti G, Di Perri G, D'Avolio A. Vitamin D

pathway gene polymorphisms and hepatocellular carcinoma in chronic

hepatitis C-affected patients treated with new drugs. Cancer Chemother

Pharmacol. 2018 Mar;81(3):615-620.

- Cusato J, De Nicol. A, Boglione L, Favata F, Ariaudo A, Mornese Pinna S,

Carcieri C, Guido F, Avataneo V, Cariti G, Di Perri G, D'Avolio A. Vitamin D

pathway genetic variants are able to influence sofosbuvir and its main

metabolite pharmacokinetics in HCV mono-infected patients. Infect Genet

Evol. 2018 Jun;60:42-47.

- Boglione L, Pinna SM, Lupia T, Cariti G, Di Perri G. Retreatment with

sofosbuvir/velpatasvir in cirrhotic patients with genotype 4 who failed a

previous interferon-free regimen: a case series. Antivir Ther. 2018 Feb 14.

- Boglione L, Cusato J, Pinna SM, De Nicol. A, Cariti G, Di Perri G, D'Avolio A.

Role of ribavirin in the treatment of hepatitis C virus-associated mixed

cryoglobulinemia with interferon-free regimens. Arch Virol. 2018

Apr;163(4):961-967.

Pagina 3/4 - Curriculum vitae di

Simone Mornese Pinna (MD)

Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu

© Unione europea, 2002-2010 24082010

- Cusato J, De Nicol. A, Boglione L, Favata F, Ariaudo A, Mornese Pinna S,

Carcieri C, Guido F, Avataneo V, Cariti G, Di Perri G, D'Avolio A.

Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. J

Antimicrob Chemother. 2018 Mar 2.

- Boglione L, De Nicol. A, Mornese Pinna S, Cusato J, Cariti G, Di Perri G,

D'Avolio A. Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C

Virus Infection Taking Methadone: A Prospective Analysis. Eur Addict Res.

2018;24(4):184-188.

- Cusato J, De Nicol. A, Boglione L, Favata F, Ariaudo A, Pinna SM, Carcieri C,

Guido F, Cariti G, Di Perri G, D'Avolio A. Vitamin D pathway gene

polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1

month of therapy. Pharmacogenomics. 2018 Jun 1;19(8):701-707.

- Giacobbe DR, Corcione S, Salsano A, Del Puente F, Mornese Pinna S, De Rosa

FG, Mikulska M, Santini F, Viscoli C. Current and emerging pharmacotherapy

for the treatment of infections following open-heart surgery. Expert Opin

Pharmacother. 2019 Feb 20:1-22.

- Corcione S, Sidoti F, Costa C, Mornese Pinna S, Bonetto C, Urbino R, Cavallo R,

De Rosa FG. V348I mutation in UL23 gene of human herpesvirus 1 in a case of

herpetic hepatitis and haemophagocytic lymphohistiocytosis. New Microbes

New Infect. 2019 Mar 14;29:100529. doi: 10.1016/j.nmni.2019.100529.

- Corcione S, Lupia T, Maraolo AE, Mornese Pinna S, Gentile I, De Rosa FG.

Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship.

Curr Opin Infect Dis. 2019 Dec;32(6):663-673.

- Corcione S, Sidoti F, Costa C, Mornese Pinna S, Bonetto C, Urbino R, Cavallo R,

De Rosa FG. 348I mutation in UL23 gene of human herpesvirus 1 in a case of

herpetic hepatitis and haemophagocytic lymphohistiocytosis. New Microbes

New Infect. 2019 Mar 14;29:100529. doi: 10.1016/j.nmni.2019.100529.

eCollection 2019 May.

- Lupia T, Corcione S, Guerrera F, Costardi L, Ruffini E, Mornese Pinna S, De Rosa

FG. Pulmonary Echinococcosis or Lung Hydatidosis: A Narrative Review. Surg

Infect (Larchmt). 2020 Dec 9. doi: 10.1089/sur.2020.197. PMID: 33297827.

- Lupia T, Corcione S, Mornese Pinna S, De Rosa FG. New cephalosporins for the

treatment of pneumonia in internal medicine wards. J Thorac Dis. 2020

Jul;12(7):3747-3763. doi: 10.21037/jtd-20-417. PMID: 32802454; PMCID:

PMC7399401.

- Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019

novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob Antimicrob

Resist. 2020 Jun;21:22-27. doi: 10.1016/j.jgar.2020.02.021. Epub 2020 Mar 7.

PMID: 32156648; PMCID: PMC7102618.